JERSEY CITY, NJ, USA I January 30, 2025 I Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved AVTOZMA® (CT-P47, ...

Leading the charge for the Eagles on Super Bowl Sunday was Pennsylvania native, Oscar nominee, and die-hard Philadelphia fan ...

Bradley Cooper, alongside eight-year-old superfan Declan LeBaron, provided a heartwarming introduction for the Philadelphia ...

Declan LeBaron, an 8-year-old Philadelphia Eagles super fan, told Fox News Digital how he felt when he was surprised by ...

Autoimmune disorders in children can cause symptoms often mistaken for common childhood illnesses. More precise diagnoses and ...

The FDA's approval is grounded in an evidence totality and comprehensive data package, which includes outcomes from a study.

The US Food and Drug Administration (FDA) has approved Avtozma (CT-P47, tocilizumab-anoh) in both an intravenous (IV) and ...

The biosimilar will be available in both subcutaneous and intravenous formulations and has nearly all the same indications as ...

Jersey City, New Jersey Saturday, February 1, 2025, 16:00 Hrs [IST] ...

The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both intravenous and subcutaneous formulations, according to a press release.

Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, ...

The FDA approved Avtozma, a tocilizumab biosimilar developed by Celltrion, for the treatment of several rheumatic conditions.